Short answer
TransMedics Group, Inc. (TMDX) filed an 8-K current report with the SEC on November 5, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results announced for the quarter ended September 30, 2026.
TransMedics Group, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results announced for the quarter ended September 30, 2026
- Full operating and financial details available in Exhibit 99.1, the company’s earnings press release
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $203.0M, up 41%, with organic growth 35%, confirming strong OCS adoption and logistics demand
- Service revenue $89.6M, up 60%, outpaced product revenue growth and increased mix pressure on gross margin
- Net income $17.1M, down from $24.3M, while operating margin fell to 13.9% from 16.2% amid expansion investments
- FY2026 revenue guidance raised to $764M-$774M, including approximately $14M from PAD Aviation, implying 26%-28% growth
- ENHANCE Heart Part B and DENOVO Lung IDE approvals, plus Italy’s first logistics tender, expand near-term clinical and international catalysts
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other TransMedics Group, Inc. 8-K filings
Get the next TMDX 8-K as it lands
Follow TMDX for push alerts, or ask the research agent what this filing means.